EUCTR2005-000807-33-IT进行中（未招募）不适用
A randomized, double blind, two-arms placebo-controlled, parallel group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 740
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
3 期
A clinical trial to study the effects of Ashwagandha in patients with stress and anxiety having cardiovascular comorbidities.CTRI/2023/07/054711Dr. Willmar Schwabe India Pvt. Ltd60
进行中（未招募）
2 期
The effects of Muno-IgYTM on immune function in healthy adult volunteersISRCTN51932144IGY Immune Technologies & Life Sciences, Inc.28
进行中（未招募）
1 期
A two-arm, randomised, double-blind, placebo-controlled, multicenter phase II study to evaluate safety and tolerability and to explore the neuroprotective effect of atacicept as assessed by Optical Coherence Tomography (OCT) in subjects with Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) over a 36 week treatment course - Atacicept in Optic Neuritis, Phase IIOptic NeuritisMedDRA version: 9.1Level: PTClassification code 10030942Term: Optic neuritisEUCTR2007-003925-26-CZMerck Serono S.A. - Geneva34
进行中（未招募）
1 期
A two-arm, randomised, double-blind, placebo-controlled, multicenter phase II study to evaluate safety and tolerability and to explore the neuroprotective effect of atacicept as assessed by Optical Coherence Tomography (OCT) in subjects with Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) over a 36 week treatment course - Atacicept in Optic Neuritis, Phase IIMedDRA version: 9.1Level: PTClassification code 10030942Term: Optic neuritisOptic NeuritisEUCTR2007-003925-26-FRMerck Serono International S.A.82
进行中（未招募）
不适用
A two-arm, randomised, double-blind, placebo-controlled, multicenter phase II study to evaluate safety and tolerability and to explore the neuroprotective effect of atacicept as assessed by Optical Coherence Tomography (OCT) in subjects with Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) over a 36 week treatment course - Atacicept in Optic Neuritis, Phase IIMedDRA version: 9.1Level: PTClassification code 10030942Term: Optic neuritisOptic NeuritisEUCTR2007-003925-26-DEMerck Serono S.A. - Geneva34